Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral Mucosal Reprogramming in Allergic Asthma
NCT05331170Phase 2Recruiting
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Apr 2023
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial (3 arms), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoints: ZEB-1 Expression, Type III Interferon Level and 2 more. Started Apr 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05331170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331170.